Valeant Pharmaceuticals repays $300 million of senior secured loans

By Tali Rackner

Minneapolis, Jan. 3 – Valeant Pharmaceuticals International, Inc. paid down an additional $300 million of its senior secured term loans with cash on hand, according to a press release.

In total, the company has now reduced its debt by more than $6.5 billion since the end of the first quarter of 2016.

As of Dec. 31, Valeant’s total debt was about $25.7 billion.

The issuer is a Laval, Quebec-based specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.